Zymogenetics, Inc.

Frederick J Ramsdell

Stephen R Jaspers

Zeren Gao

Mark W Rixon

Stacey R Dillon

Steven D Levin

Cameron Brandt

Cecile Krejsa

Eugene C Yi

Eric M Chadwick

Cecile M Krejsa

Edward D Howard

Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinant IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21  antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells, Tcells or T17 cells.

Methods of treatment using anti-human IL-21 monoclonal antibodies

Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinat IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells Tcells or T17 cells.

Anti-human IL-21 monoclonal antibodies

Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinant IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells Tcells or T17 cells.

Growing community of inventors

Bainbridge Island, WA, United States of America

Frederick J Ramsdell